Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 4 of 47 · 2234 articles
The work suggests a new mechanism linking macrophage-driven ECM remodeling to protection of enteric neurons and reduced colitis in preclinical models, which could point to future therapies aimed at preventing neuronal...
If your colonoscopy found inflammation only in the terminal ileum, additional imaging with CTE identified more proximal small-bowel disease in about half of patients and often led to a diagnosis of Crohn’s disease.
Unaffected family members often worry about their own risk and may make dietary changes based on beliefs rather than evidence. Understanding these perceptions can help clinicians give clearer, balanced guidance about...
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...
The review outlines new research tools for investigating whether mycobacteria contribute to Crohn’s disease and how the microbiome might influence infection and intestinal inflammation, which could eventually inform...
If validated, blood protein signatures that appear years before symptoms could help identify people at higher risk of Crohn’s disease and point to lifestyle or dietary measures that alter early biology.
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Procedures and surgery. The original article is from gastroendonews.com.
Public figures talking about Crohn’s disease can raise awareness about how flares affect weight, appearance, hydration, and daily life, and may reduce stigma from uninformed comments.
The study suggests a specific microbial metabolite, 3‑HPA, can link cold exposure to worse colitis by changing the microbiome and harming epithelial cell mitochondria and barrier function — a possible new mechanistic...
A locally delivered rifamycin formulation reduced macroscopic and microscopic colonic damage in an acute rat model of colitis, suggesting a potential new local therapeutic approach worth further preclinical evaluation.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...
Pouchitis is a common, sometimes chronic complication after IPAA surgery for ulcerative colitis and can substantially affect quality of life. If topical 5-ASA prevents pouchitis, it could offer a simple prophylactic...
This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...
The study links NEAT1, a long noncoding RNA, to neutrophil-driven mucosal inflammation in ulcerative colitis and suggests NEAT1 affects neutrophil activity via glycolysis. That points to a new molecular pathway that...
A new molecular finding (PTPRK::RSPO3 fusion) in a serrated colorectal lesion from a person with ulcerative colitis may be relevant to understanding dysplasia and cancer pathways in IBD, and could prompt further study of...
Coexistence of ulcerative colitis and collagenous colitis is rare but can change diagnosis and management. Stool calprotectin and biopsies helped identify and monitor disease activity, and adjusting mesalazine coincided...
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...
Anemia is a common complication of IBD and can worsen quality of life. This study suggests endotoxins leaking from an inflamed gut may drive anemia through TLR4 on tissue-resident macrophages, highlighting a possible new...
Auto-brewery syndrome can cause unexplained intoxication-like symptoms and may be under-recognized in people with Crohn’s disease. Recognizing gut fermentation as a possible cause can affect diagnostic testing and...
Smoking and similar nicotine-product use after Crohn's surgery appears linked to higher rates of endoscopic recurrence, which may affect postoperative monitoring and secondary-prevention strategies. Patients using HNBT...
This study highlights a potential new molecular player (ABLIM3) involved in colitis-related epithelial and cytoskeletal changes. Understanding such mechanisms could eventually point to new targets for therapies or...
The review shows psychotherapies can improve quality of life and reduce anxiety and depression in people with IBD, outcomes that matter for daily functioning even when intestinal symptoms may not change.
This work suggests a new way Crohn’s disease might begin: a weaker early immune response (linked to NOD2 gene defects) allows small intestinal infections to persist and later trigger the inflammation that causes...
Postoperative endoscopic recurrence after ileocolic resection is an important risk for people with Crohn’s disease; this study links HNBT and possibly e-cigarette use to higher recurrence rates, which could affect...
This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...
Timing of therapies and daily behaviors may affect drug metabolism, immune activity, and symptom patterns in IBD. Considering when treatments are given could potentially improve response, reduce toxicity, and help...
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
People with IBD who need weight loss or have metabolic problems may encounter GLP-1 receptor agonists; this review suggests those drugs reduced weight and improved metabolic measures in people with IBD without clear...
Accurate measurement of physical activity matters because it’s linked to symptoms, fitness, and overall health.
The study describes a new ultrasound-activated nanozyme that reduced intestinal inflammation and promoted mucosal repair in preclinical IBD models by scavenging ROS and modulating the gut microbiota—an approach that...
Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Functional...
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.
A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.
This trial tests whether the common sweetener sucralose alters the gut microbiome in people with Crohn’s disease in remission compared with healthy volunteers.
Diagnosis between UC, Crohn’s disease, and unclassified IBD can change in a meaningful minority of patients over years. Awareness of common reasons for reclassification (segmental disease, strictures) helps guide...
Dietary patterns like the Mediterranean diet may reduce inflammation and improve quality of life for people with Crohn’s disease by beneficially altering the gut microbiome and inflammatory markers. That could offer a...
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...
Mesalazine is commonly used in ulcerative colitis; recognizing rare but serious myocarditis linked to it can lead to rapid treatment changes and recovery. Distinguishing drug-induced myocarditis from IBD-related...
The study suggests a targeted microbiome-based drug (sialidase inhibitor) may protect the mucus barrier and improve symptoms in ulcerative colitis without the broad disruption caused by antibiotics, which could be...
Sarcopenia (low muscle mass) was linked with worse outcomes in Crohn’s disease and, combined with fecal calprotectin and disease behaviour, formed a score that better predicted unfavourable courses. Identifying at-risk...
People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
This study suggests a plant extract might boost ketone-body levels and reduce colitis-like inflammation in a mouse model — a concept that could inform future dietary or therapeutic research for ulcerative colitis but is...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
